Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD.

J Allergy Clin Immunol. 2007 Sep;120(3):680-7.

PMID:
17628645
2.

FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Yamada Y, Cancelas JA.

Int Arch Allergy Immunol. 2010;152 Suppl 1:101-5. doi: 10.1159/000312134. Review.

3.

Eosinophilia in mast cell disease.

Kovalszki A, Weller PF.

Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Review.

5.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG.

Curr Opin Hematol. 2004 Jan;11(1):51-7. Review.

PMID:
14676627
6.

Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.

Gotlib J, Akin C.

Semin Hematol. 2012 Apr;49(2):128-37. doi: 10.1053/j.seminhematol.2012.01.007. Review.

PMID:
22449623
7.

Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.

Yamada Y, Cancelas JA, Rothenberg ME.

Int Arch Allergy Immunol. 2009;149 Suppl 1:102-7. doi: 10.1159/000211381. Review.

PMID:
19494514
8.

Modern diagnosis and treatment of primary eosinophilia.

Tefferi A.

Acta Haematol. 2005;114(1):52-60. Review.

PMID:
15995325
9.

[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].

Borbényi Z.

Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. Review. Hungarian.

PMID:
15921304
10.

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O.

Int J Hematol. 2007 Oct;86(3):233-7. Review.

PMID:
17988989
11.

Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.

Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T.

Br J Haematol. 2006 Sep;134(5):547-9. Review. No abstract available.

PMID:
16856885
12.

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.

Ustun C, DeRemer DL, Akin C.

Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Review.

PMID:
21641642
13.

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.

Gotlib J.

Acta Haematol. 2005;114(1):7-25. Review.

PMID:
15995322
14.
15.

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.

Pardanani A, Tefferi A.

Leuk Res. 2004 May;28 Suppl 1:S47-52. Review.

PMID:
15036941
16.

FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.

Cools J.

Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Review.

PMID:
16089297
17.

Systemic mastocytosis: bone marrow pathology, classification, and current therapies.

Pardanani A.

Acta Haematol. 2005;114(1):41-51. Review.

PMID:
15995324
18.

Diagnostic complexities of eosinophilia.

Montgomery ND, Dunphy CH, Mooberry M, Laramore A, Foster MC, Park SI, Fedoriw YD.

Arch Pathol Lab Med. 2013 Feb;137(2):259-69. doi: 10.5858/arpa.2011-0597-RA. Review.

PMID:
23368869
19.

Clinical, genetic, and therapeutic insights into systemic mast cell disease.

Tefferi A, Pardanani A.

Curr Opin Hematol. 2004 Jan;11(1):58-64. Review.

PMID:
14676628
20.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Feb;14(1):23-31. Review. Erratum in: Semin Cancer Biol. 2004 Aug;14(4):306. Corrected and republished in: Semin Cancer Biol. 2004 Aug;14(4):307-15.

PMID:
14757533
Items per page

Supplemental Content

Support Center